Wikisage, the free encyclopedia of the second generation, is digital heritage
Belzutifan: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(→ATC) |
||
| Line 14: | Line 14: | ||
[[File:Buecher_Regal_636.jpg|32px]] | [[File:Buecher_Regal_636.jpg|32px]] | ||
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref> | Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref> | ||
[[File:Protein_VHL_PDB_1lm8.png|thumb|VHL protein]] | |||
==External links== | |||
[[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S]] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323 | |||
{{wikidata|Q27456641}} | {{wikidata|Q27456641}} | ||
Revision as of 23:42, 13 August 2021
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]
ATC
none
|
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]
External links
[Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
| References: |
|